AMLX vs TECH · rev $87.4M vs P/E 65, rev $1.22B
Amylyx Pharmaceuticals Inc (AMLX) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported AMLX revenue for 2024-12-31 was $87.4M. Net income was -$301.7M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AMLX currently screens at market cap $561.6M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
AMLX currently screens at market cap $561.6M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the AMLX and TECH stock pages for the full models.
Not investment advice.